|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7-8
|
|
pubmed:dateCreated |
1985-9-19
|
|
pubmed:abstractText |
Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m2) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m2. Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0361-5960
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
897-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:4040427-Adult,
pubmed-meshheading:4040427-Aged,
pubmed-meshheading:4040427-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:4040427-Cisplatin,
pubmed-meshheading:4040427-Cytarabine,
pubmed-meshheading:4040427-Drug Administration Schedule,
pubmed-meshheading:4040427-Drug Evaluation,
pubmed-meshheading:4040427-Fatigue,
pubmed-meshheading:4040427-Female,
pubmed-meshheading:4040427-Humans,
pubmed-meshheading:4040427-Infusions, Parenteral,
pubmed-meshheading:4040427-Kidney Diseases,
pubmed-meshheading:4040427-Male,
pubmed-meshheading:4040427-Middle Aged,
pubmed-meshheading:4040427-Nausea,
pubmed-meshheading:4040427-Neoplasms
|
|
pubmed:articleTitle |
Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
